2024 - 2032 年非鴉片類止痛貼市場機會、成長動力、產業趨勢分析與預測

Non-opioid Pain Patch Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月24日 | 出版商:

Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球非鴉片類止痛貼片市場規模達8.283億美元，預計2024年至2032年複合年成長率為6.6%。提供有針對性的疼痛緩解，而沒有與鴉片類藥物相關的風險。這些貼片可有效治療慢性、神經性、肌肉骨骼和術後疼痛，提供鴉片類藥物的安全替代品，滿足對非成癮性、有效疼痛管理解決方案的需求。疼痛管理的研究和開發不斷增加，包括 NIH Heal Initiative 等舉措，該計劃的重點是推動慢性疼痛治療並減少鴉片類藥物使用障礙 (OUD) 和用藥過量率，從而推動了市場的發展。此類計畫正在促進開發更安全、不含鴉片類藥物的治療方法，從而顯著增加對非鴉片類止痛貼的需求。

從產品來看，市場包括利多卡因、雙氯芬酸、水楊酸甲酯、辣椒素、酮洛芬和其他止痛貼片。利多卡因細分市場在 2023 年以 3.57 億美元的收入引領市場，由於人們對鴉片類替代品的興趣不斷增加，顯示出強勁的成長潛力。與鴉片類藥物相關的高成癮率和死亡率促使醫療保健提供者和患者轉向更安全的選擇，例如利多卡因貼片，它可以緩解局部疼痛，而沒有成癮風險。在治療應用方面，慢性疼痛管理領域的非鴉片類止痛貼片市場在 2023 年佔據 42.4% 的市場佔有率，預計將顯著成長。

非鴉片類藥物貼片已被證明可以有效控制慢性疼痛，通常與口服藥物相當，並且具有持續、局部緩解的額外優勢。臨床研究強調了它們的實用性，促使更多人採用長期疼痛管理。美國主導市場，2023 年營收為 2.443 億美元，預計將出現強勁成長。政府對鴉片類藥物處方的監管，包括 FDA 提倡非鴉片類藥物選擇的指南，刺激了對含有利多卡因、雙氯芬酸和辣椒素的止痛貼片的需求，用於治療慢性和急性疼痛。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	8.283 億美元
預測值	15億美元
複合年成長率	6.6%

此外，美國老年人口不斷增加，肌肉骨骼疾病、慢性關節疼痛和關節炎的發生率更高，這進一步推動了對非鴉片類疼痛管理解決方案的需求。

產業生態系統分析
產業影響力
- 成長動力
  - 鴉片類藥物處方的使用越來越多
  - 疼痛相關疾病的發生率上升
  - 與其他形式的藥物相比，非鴉片類止痛貼片具有優勢
  - 疼痛管理治療的研發不斷增加
- 產業陷阱與挑戰
  - 長期使用非鴉片類止痛貼片所引起的副作用
  - 替代治療的可用性
成長潛力分析
監管環境
- 美國
- 歐洲
技術景觀
- 核心技術
- 鄰近技術
報銷場景
定價分析
- 按地區
- 依產品
消費者行為分析
未來市場趨勢
專利分析
利潤率分析
管道分析
臨床試驗情況
差距分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品類型，2021 - 2032

主要趨勢
利多卡因貼劑
雙氯芬酸貼劑
水楊酸甲酯貼片
辣椒素貼片
酮洛芬貼劑
其他補丁

第 6 章：市場估計與預測：按治療應用分類，2021 - 2032 年

主要趨勢
慢性疼痛
急性疼痛
神經性疼痛
肌肉骨骼疼痛
其他治療應用

第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第 9 章：公司簡介

Acorda Therapeutics
AdhexPharma
Endo Pharmaceuticals
Glaxo SmithKline
Grunenthal
Hisamitsu Pharmaceutical
IBSA Institut Biochimique
Johnson & Johnson
Mylan (Viatris)
Nichiban
Pfizer
ProSolus
Sanofi
Teikoku Seiyaku
Teva Pharmaceuticals

簡介目錄

Product Code: 11974

The Global Non-opioid Pain Patch Market reached USD 828.3 million in 2023 and is projected to grow at a CAGR of 6.6% from 2024 to 2032. Non-opioid pain patches are transdermic devices designed to deliver medication directly through the skin, providing targeted pain relief without the risks associated with opioids. Effective in managing chronic, neuropathic, musculoskeletal, and post-surgical pain, these patches offer a safe alternative to opioid medications, addressing the need for non-addictive, effective pain management solutions. The market is propelled by increasing research and development in pain management, including initiatives like the NIH Heal Initiative, which focuses on advancing chronic pain treatment and reducing opioid use disorder (OUD) and overdose rates. Such programs are fostering the development of safer, opioid-free treatments, significantly boosting the demand for non-opioid pain patches.

Product-wise, the market includes lidocaine, diclofenac, methyl salicylate, capsaicin, ketoprofen, and other pain-relief patches. The lidocaine segment led the market in 2023 with revenues of USD 357 million, showing strong growth potential due to the escalating interest in opioid alternatives. The high rates of addiction and fatalities linked to opioid medications have pushed healthcare providers and patients toward safer options like lidocaine patches, which deliver localized pain relief without addiction risks. Regarding therapeutic application, the non-opioid pain patch market from the Chronic pain management held a significant 42.4% market share in 2023 and is expected to see notable growth.

Non-opioid patches have proven effective in managing chronic pain, often comparable to oral medications, with the added advantage of continuous, localized relief. Clinical studies underscore their utility, prompting greater adoption for long-term pain management. U.S. dominated the market, generating USD 244.3 million in revenue in 2023, and is anticipated to experience strong growth. Government regulations on opioid prescriptions, including FDA guidelines promoting non-opioid options, have fueled demand for pain patches containing lidocaine, diclofenac, and capsaicin for both chronic and acute pain.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$828.3 Million
Forecast Value	$1.5 Billion
CAGR	6.6%

Additionally, the U.S. has a growing elderly population, which experiences higher rates of musculoskeletal conditions, chronic joint pain, and arthritis-further driving the need for non-opioid pain management solutions.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing use of opioid prescriptions
  - 3.2.1.2 Rising incidence of pain related disorders
  - 3.2.1.3 Advantages offered by non-opioid pain patches over other forms of medications
  - 3.2.1.4 Rising R&D in pain management treatments
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects caused by prolonged use of non-opioid pain patches
  - 3.2.2.2 Availability of alternative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Reimbursement scenario
3.7 Pricing analysis
- 3.7.1 By region
- 3.7.2 By product
3.8 Consumer behavior analysis
3.9 Future market trends
3.10 Patent analysis
3.11 Profit margin analysis
3.12 Pipeline analysis
3.13 Clinical trial landscape
3.14 Gap analysis
3.15 Porter's analysis
3.16 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Lidocaine patches
5.3 Diclofenac patches
5.4 Methyl Salicylate patches
5.5 Capsaicin patches
5.6 Ketoprofen patches
5.7 Other patches

Chapter 6 Market Estimates and Forecast, By Therapeutic Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Chronic pain
6.3 Acute pain
6.4 Neuropathic pain
6.5 Musculoskeletal pain
6.6 Other therapeutic applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE